DERM trades 162.9% below Wall Street's consensus target of $11.75.
Last 12 months price action with 12-month analyst target path
The base valuation assumes DERM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Journey Medical Corporation (DERM) has a Wall Street consensus price target of $11.75, based on estimates from 3 covering analysts. With the stock currently trading at $4.47, this represents a potential upside of +162.9%. The company has a market capitalization of $123M.
Analyst price targets range from a low of $10.50 to a high of $13.00, representing a 21% spread in expectations. The median target of $11.75 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, DERM trades at a trailing P/E of -20.1x. Analysts expect EPS to grow +43.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SKINSkinHealth Systems Inc. | $102M | $15.71 | $8.50 | -45.9% | Hold | — | 14 |
 PRGOPerrigo Company plc | $2.2B | $15.85 | $36.20 | +128.4% | Hold | 6.9x | 36 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 PODDInsulet Corp. | $10.1B | $146.51 | $181.18 | +23.7% | Buy | 22.5x | 50 |
 YARWYarrow Bioscience Inc | $13M | $15.60 | — | — | — | — | — |
 PCRXPacira BioSciences, Inc. | $1.4B | $36.43 | $31.60 | -13.3% | Hold | 12.6x | 36 |
 MCKMcKesson Corporation | $123.8B | $1060.84 | $983.13 | -7.3% | Buy | 23.8x | 31 |
 CAHCardinal Health, Inc. | $63.6B | $271.72 | $279.33 | +2.8% | Buy | 21.6x | 33 |
 HSICHenry Schein, Inc. | $9.8B | $86.05 | $97.14 | +12.9% | Buy | 15.7x | 34 |
 ACRSAclaris Therapeutics, Inc. | $545M | $3.90 | $9.50 | +143.6% | Buy | — | 17 |
Quick answers to the most common questions about buying DERM stock.
The consensus Wall Street price target for DERM is $11.75, representing 162.9% upside from the current price of $4.47. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
DERM has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $11.75 implies 162.9% upside from current levels.
DERM's current price is $4.47 with a consensus target of $11.75 (162.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $13 for DERM, while the most conservative target is $10.5. The consensus of $11.75 represents the median expectation. These targets typically reflect 12-month expectations.
DERM is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DERM stock forecast based on 3 Wall Street analysts shows a consensus price target of $11.75, with estimates ranging from $10.5 (bear case) to $13 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on DERM, with a "Buy" consensus rating and $11.75 price target (162.9% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DERM analyst price targets range from $10.5 to $13, a 21% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11.75 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.